# Remo Panaccione

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/remo-panaccione/

## Facts

| Field | Value |
| --- | --- |
| Citations | 63,282 |
| Field | Inflammatory Bowel Disease |
| h-index | 108 |
| i10-index | 397 |
| Last Known Institution | University of Calgary |
| OpenAlex ID | https://openalex.org/A5008149243 |
| ORCID iD | https://orcid.org/0000-0002-5247-940X |
| Works | 1,320 |

## Researcher papers

- [Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies](https://scholariq.org/papers/worldwide-incidence-and-prevalence-of-inflammatory-bowel-disease-in-the-21st/)
- [Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target](https://scholariq.org/papers/selecting-therapeutic-targets-in-inflammatory-bowel-disease-stride-determining/)
- [Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/ustekinumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Crohn’s disease](https://scholariq.org/papers/crohn-s-disease/)
- [Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study](https://scholariq.org/papers/effects-of-adalimumab-therapy-on-incidence-of-hospitalization-and-surgery-in/)
- [Global evolution of inflammatory bowel disease across epidemiologic stages](https://scholariq.org/papers/global-evolution-of-inflammatory-bowel-disease-across-epidemiologic-stages/)
- [Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection](https://scholariq.org/papers/infliximab-reduces-endoscopic-but-not-clinical-recurrence-of-crohn-s-disease/)
- [Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial](https://scholariq.org/papers/ustekinumab-versus-adalimumab-for-induction-and-maintenance-therapy-in-biologic/)
- [Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease](https://scholariq.org/papers/deep-remission-at-1-year-prevents-progression-of-early-crohn-s-disease/)
- [Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting](https://scholariq.org/papers/management-of-patients-with-crohn-s-disease-and-ulcerative-colitis-during-the/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)
- [Autoimmune and Inflammatory Disorders](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

## Researcher university

- [University of Calgary](https://scholariq.org/institutions/university-of-calgary/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.